Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06682611CT.gov Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. | — | Not Yet Recruiting | — | — | — |
NCT01960829CT.gov Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study | — | Unknown | — | — | — |
NCT01499160CT.gov Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer | — | Terminated | — | — | — |
NCT01190241CT.gov Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study | — | Terminated | — | — | — |
NCT01122199CT.gov Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01115803CT.gov A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT00426530CT.gov Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00317720CT.gov Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | Shanghai Runshi Pharmaceutical Technology Co., Ltd | P2 | B · 59 |
| Oxaliplatin | Ruijin Hospital | P4 | BBB |
| Fluorouracilum | Ruijin Hospital | P4 | BBB |
| Irinotecan | Eli Lilly and Company | P4 | BBB |
| Dexasone | Janssen Research & Development, LLC | P2 | BBB |
| Atezolizumab | UNC Lineberger Comprehensive Cancer Center | P2/3 | BB |
| Ipilimumab | 7 Hills Pharma, LLC | P3 | BB |
| Trastuzumab | City of Hope Medical Center | P3 | BB |
| Margetuximab | MacroGenics | P3 | BB |
+41 more in the Metastatic Neoplasm cohort
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Everolimus in Metastatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-metastatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →